{'fraction_non_alphanumeric': 0.026690391459074734, 'fraction_numerical': 0.006227758007117438, 'mean_word_length': 5.081081081081081, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Treatment of the hemolytic-uremic syndrome with streptokinase and heparin (author's transl)].

In a clinical study we treated 16 children, suffering from severe hemolytic-uremic syndrome (HUS), with streptokinase or heparin. All children received the same symptomatic treatment (early dialysis, transfusion of packed red cells). A control group of 10 children was only treated symptomatically. No difference could be shown in clinical grading of severity. We analysed the results of the acute phase and of a follow up study of 1-5 years, which is not yet complete. The results show, that heparin could not improve the prognosis of HUS in comparison to streptokinase or symptomatic treatment. The results of streptokinase treatment were not better than in the control group. In 4 children we saw severe bleeding complications of streptokinase therapy. Accepting the complication rate of a drug and the incidence of chronic renal disease as criterium of the efficacy of drug treatment in severe HUS, streptokinase and heparin are not indicated. We believe, that patients should be managed symptomatically with early dialysis.